Global Opportunity RPS Diagnostics already has a commercial footprint outside the United States with FebriDx available in Australia, Canada, Europe, the Gulf Cooperation Council countries, Saudi Arabia, Singapore, and the United Kingdom, presenting a ready-made entry path for regional expansion discussions in similar markets and potential U.S. market access partnerships.

Clinical Differentiation FebriDx provides a rapid 15-minute fingerstick test that differentiates bacterial from viral causes of fever in acute respiratory infections with a high negative predictive value, offering a compelling value proposition for clinics seeking to reduce unnecessary antibiotic prescriptions and improve antibiotic stewardship.

Strategic Partnerships Past collaboration with Atomo Diagnostics and a history of rapid testing innovation indicate openness to co-development and distribution partnerships, suggesting sales opportunities through OEM or co-branded products with complementary device manufacturers and healthcare distributors.

Market Readiness With an established presence in multiple international markets and a track record of recognition (Rapid Testing Innovation Award), there is credibility to approach regional health systems, pharmacies, and urgent care networks about point-of-care adoption and channel expansion.

Growth Signals Revenue is in the low-to-mid single digits but combined with a focused product niche and ongoing development, there is potential to upsell to existing distributors, pursue hospital-based pilots, and explore U.S. regulatory pathways to unlock broader access and scale.